Sun Pharmaceutical Industries Ltd
₹1825.30
(-0.03%)
Fri, 13 Mar 2026, 03:23 am
Health Technology
Pharmaceuticals: Major
24.5KSun Pharmaceutical Industries PE Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 31.28 | 27.10 | 17.15 | 12.67 | 27.45 | 25.25 | 22.16 | 28.41 | 37.72 | 54.09 | 43.36 | 23.71 | 56.72 | 43.14 | 22.45 | 49.38 | 67.07 | 27.84 | 40.60 | 38.10 |
| Price to book ratio | 10.13 | 7.36 | 5.11 | 3.27 | 4.73 | 4.82 | 4.82 | 5.65 | 6.41 | 8.26 | 5.98 | 4.50 | 3.10 | 2.78 | 1.87 | 3.09 | 4.57 | 4.21 | 6.11 | 5.77 |
| Price to sales ratio | 11.24 | 10.20 | 7.75 | 5.51 | 9.73 | 8 | 7.37 | 7.54 | 7.42 | 9.01 | 7.02 | 5.28 | 4.50 | 3.96 | 2.57 | 4.28 | 5.68 | 5.37 | 8.12 | 7.98 |
| Price to cash flow ratio | 69.54 | 65.55 | 41.69 | 10.24 | 39.78 | 18.77 | 25.49 | 24.16 | 28.72 | 45.90 | 29.13 | 23.19 | 29.88 | 47.08 | 12.66 | 22.99 | 24.06 | 44.42 | 30.79 | 28.29 |
| Enterprise value | 183.03B | 210.29B | 244.98B | 217.46B | 351.41B | 448.32B | 554.67B | 812.03B | 1140B | 2450B | 1960B | 1630B | 1190B | 1180B | 852.95B | 1410B | 2110B | 2310B | 3760B | 3930B |
| Enterprise value to EBITDA ratio | 37.35 | 31.33 | 15.87 | 11.66 | 29.72 | 22.74 | 17 | 16.52 | 15.43 | 30.29 | 22.91 | 16.76 | 21.23 | 17.62 | 11.70 | 16.40 | 20.56 | 19.84 | 31.03 | 26.16 |
| Debt to equity ratio | 1.18 | 0.40 | 0.03 | 0.03 | 0.02 | 0.04 | 0.03 | 0.02 | 0.14 | 0.35 | 0.26 | 0.27 | 0.27 | 0.25 | 0.18 | 0.08 | 0.03 | 0.12 | 0.05 | 0.03 |
| Return on equity % | 42.14 | 35.95 | 38.30 | 30.20 | 18.17 | 20.98 | 24.47 | 21.96 | 18.76 | 20.56 | 15.51 | 20.47 | 5.59 | 6.70 | 8.69 | 6.33 | 6.93 | 16.29 | 16.01 | 16.09 |
Sun Pharmaceutical Industries Ltd Price to Earnings Ratio
The Sun Pharmaceutical Industries Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Sun Pharmaceutical Industries Ltd's valuation, profitability, and overall financial performance. Tracking the Sun Pharmaceutical Industries Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA, BSE: 524715) is currently trading at ₹1825.30, with a market capitalization of ₹4378.44B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Sun Pharmaceutical Industries Ltd Price to Earnings Ratio is essential for fundamental analysis.
Sun Pharmaceutical Industries Ltd Price to Earnings Ratio Current Value
The current Sun Pharmaceutical Industries Ltd Price to Earnings Ratio stands at 38.10.
The Sun Pharmaceutical Industries Ltd Price to Earnings Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Sun Pharmaceutical Industries Ltd Price to Earnings Ratio Historical Trend
The Sun Pharmaceutical Industries Ltd Price to Earnings Ratio has shown the following historical trend:
- 2024: 38.10
- 2023: 40.60
- 2022: 27.84
- 2021: 67.07
- 2020: 49.38
The decline in Sun Pharmaceutical Industries Ltd Price to Earnings Ratio indicates improving financial efficiency or better earnings growth.
What Sun Pharmaceutical Industries Ltd Price to Earnings Ratio Indicates for Investors
The Sun Pharmaceutical Industries Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
Sun Pharmaceutical Industries Ltd Price to Earnings Ratio Analysis Summary
The Sun Pharmaceutical Industries Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Sun Pharmaceutical Industries Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Sun Pharmaceutical Industries Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800